

ACOG 2022 – KYSS North American subset data abstract

Title

Satisfaction with LNG-IUS 12 in North American women: Findings from the Kyleena® Satisfaction Study

Authors

Brian Hauck^{1*}, Kristie Baisden², Ann-Kathrin Frenz³, Keith Aqua⁴

Affiliations

¹ Department of Obstetrics and Gynecology, Foothills Hospital, University of Calgary, Calgary, Alberta, Canada

² Bayer US LLC, Whippany, New Jersey, USA

³ Bayer AG, Berlin, Germany

⁴ Virtus Research Consultants, Wellington, Florida, USA

*Presenting author

Introduction:

The real-world Kyleena® Satisfaction Study (KYSS) confirmed clinical findings that LNG-IUS 12 (Kyleena®) is associated with high satisfaction and continuation rates. We report results from North American KYSS participants.

Methods:

This observational, multinational, multicenter, single-arm cohort study was conducted from 2017 to 2018. All centers obtained institutional review board approval. Women who independently selected to use LNG-IUS 12 were enrolled. KYSS assessed LNG-IUS 12 satisfaction, continuation, and safety.

Results:

LNG-IUS 12 was successfully placed in 99/99 Canadian and 99/100 US women. Clinicians rated placement “easy” in 88 (89%) Canadian and 90 (90%) US women. 67 (68%) Canadian and 72 (72%) US women rated placement pain as none/mild.

For Canadian women, mean age was 24.2±7.0 years and 87/99 (88%) were nulliparous, compared with 26.4±7.3 years and 71/99 (72%) for US women.

Motivations for choosing LNG-IUS 12 were most commonly “no need for a contraceptive routine” (31/99 [31%] Canadian and 49/99 [50%] US women) and “high contraceptive reliability” (34/99 [34%] and 23/99 [23%], respectively).

At 12 months/premature discontinuation, 69/75 (92%) Canadian and 83/89 (93%) US women reported being very/somewhat satisfied with LNG-IUS 12; 49/74 (66%) Canadian and 64/80 (80%) US women were satisfied with their menstrual bleeding profile.

The 12-month continuation rate was 74% (73/99) for Canadian and 82% (82/100) for US women. Most discontinuations were due to loss to follow-up (16/99 [16%] and 7/100 [7%], respectively) or treatment-emergent adverse events (10/99 [10%] and 8/100 [8%], respectively).

Conclusions/Implications:

Results from North American KYSS participants demonstrate high satisfaction and continuation including among young and nulliparous women.

Word count: 250/250 words (excluding headings)